🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "huge turning point" in the effort against increasingly resistant strains of the infection, according to researchers.

A Global Public Health Issue

Cases of gonorrhoea are on the rise around the world, with data suggesting more than 82 million instances each year. Notably increased rates are reported in Africa and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the reality of growing infection rates, increasing antimicrobial resistance and the extremely scarce treatment choices currently available.”

Medical experts are deeply concerned about the increase in antibiotic-resistant strains. The WHO has designated it as a "critical concern". Recent surveillance revealed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Drugs Receive Approval

One new antibiotic, marketed under the name a brand name, was cleared by the US FDA in mid-December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers hope that specific application of this new drug will help slow the development of resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This treatment, which is additionally indicated for UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to see it through.

“This milestone signifies a huge turning point in the management of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Results and Global Access

As per data published in a prominent scientific publication, the new drug cured more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The research enrolled nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the ability to register and commercialise the drug in numerous regions with limited resources.

Medical professionals directly involved have expressed optimism. Access to a easy-to-administer therapy such as this is hailed as a "revolutionary step" for managing the epidemic. This is considered vital to alleviate the strain of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea around the world.